Journal
CANCER BIOLOGY & THERAPY
Volume 16, Issue 11, Pages 1682-1688Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/15384047.2015.1070982
Keywords
breast cancer; cell motility; microtubule; plant hormone; strigolactone; xenograft; SLs; strigolactones
Categories
Funding
- Kamin fund of The Israeli Ministry of Economy
- Chief Scientist Fund of The Israeli Ministry of Agriculture
- Georgetown SNHS research award
- Georgetown Undergraduate Research Opportunities Program, GUROP
- NIH/NCI [P30-CA051008, P30 CA051008]
- GHUCCTS [UL1 TR000101]
Ask authors/readers for more resources
Strigolactones (SLs) are a novel class of plant hormones. Previously, we found that analogs of SLs induce growth arrest and apoptosis in breast cancer cell lines. These compounds also inhibited the growth of breast cancer stem cell enriched-mammospheres with increased potency. Furthermore, strigolactone analogs inhibited growth and survival of colon, lung, prostate, melanoma, osteosarcoma and leukemia cancer cell lines. To further examine the anti-cancer activity of SLs in vivo, we have examined their effects on growth and viability of MDA-MB-231 tumor xenografts model either alone or in combination with paclitaxel. We show that strigolactone act as new anti-cancer agents in inhibition of breast cancer in xenograft model. In addition we show that SLs affect the integrity of the microtubule network and therefore may inhibit the migratory phenotype of the highly invasive breast cancer cell lines that were examined.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available